What is the value of digital endpoints in clinical studies?
Their potential is undeniable, the value is significant; and yet, widespread adoption remains a challenge.
Koneksa is thrilled to be a part of the official launch of Digital Medicine Society (DiMe)'s new project, "Building the Business Case for Digital Endpoints.” Along with industry partners, we share in the vision that digital endpoints hold the potential to improve the design and execution of clinical trials, making them more patient-centric, data-driven, and adaptable to the evolving needs of clinical research.
Learn more here, including signing up to stay up-to-date with this project and be among the first to access the project resources: https://lnkd.in/ej6YnfSi
*
*
*
Thank you to all of the collaborators Digital Medicine Society (DiMe),
AbbVie, ActiGraph, Biofourmis, BlueSkeye AI, Brain & Mind ltd, CHEO, Chugai Pharma USA, Inc., COPD Foundation, Cosinuss GmbH, Critical Path Institute (C-Path), EVMS Medicine, Evinova, FDA, Genentech, Health Advances, Merck, Mitsubishi Tanabe Pharma America, Modality.AI, OmniScience, Regeneron, Roche, Sama Therapeutics, Sanofi, Seuss+, Strados Labs, SYSNAV Healthcare, Tech Doctor, Inc., TNO, Tufts Center for the Study of Drug Development, UChicago Medicine, VeriSIM Life, WKD.SMRT, Mobilise-D , Cumulus Neuroscience, Imperial College London